An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea

Exclusion Criteria

• •Subject is pregnant, lactating or is planning to become pregnant during the study.
• •Subject has any other active dermatological condition on the face that may interfere with the conduct of the study.
• •Subject has used systemic immunosuppressants within 30 days prior to study start.
• •Subject has used systemic retinoids within 6 months prior to study start.
• •Subject has used any topical rosacea therapy within 14 days prior to study start.
• •Subject has had laser or light therapy on the face within 3 months of study start.
• •Subject is currently enrolled in an investigational drug or device study.
• •Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.
• •Subject has used vasodilators or adrenergic blocking agents within 6 weeks of study start (except subjects on stable dose for greater than 3 months).
• •Subject has active ocular rosacea and/or blepharitis/meibomianitis requiring treatment by an ophthalmologist.
• •Subject has previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics or use of the components of PDI-320.